Nanobiotix Reports Q1 2026 Operational and Financial Progress

Nanobiotix announced key operational and financial developments for Q1 2026. The company completed a follow-on offering, raising around €86.1 million, to accelerate the development of its platforms. New data from Part 1 of the Phase 2 CONVERGE study into JNJ-1900 (NBTXR3) for Stage 3 inoperable NSCLC was presented, showing an 85.7% overall response rate.

Additionally, an FDA-approved protocol amendment in the NANORAY-312 study, removing the interim analysis, was instrumental in expediting the final analysis. Nanobiotix also shared insights into its Nanoprimer platform at the 2026 AACR Meeting, highlighting improvements in bioavailability and reduced toxicity.

As of March 31, 2026, the company had €42.1 million in cash, positioning it to meet operational requirements until 2029, aligning with its financial strategy.